Leukemia, Hairy Cell: A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Leukemia, Lymphocytic, Chronic, B-Cell: A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.Aminosalicylic Acids: A group of 2-hydroxybenzoic acids that can be substituted by amino groups at any of the 3-, 4-, 5-, or 6-positions.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Leukemia, Prolymphocytic: A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.PolandSplenectomy: Surgical procedure involving either partial or entire removal of the spleen.2-Chloroadenosine: 2-Chloroadenosine. A metabolically stable analog of adenosine which acts as an adenosine receptor agonist. The compound has a potent effect on the peripheral and central nervous system.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Retreatment: The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.Antibodies, Monoclonal, Murine-Derived: Antibodies obtained from a single clone of cells grown in mice or rats.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Adenine NucleotidesBenzenesulfonates: Organic salts and esters of benzenesulfonic acid.Drug Screening Assays, Antitumor: Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Recurrence: The return of a sign, symptom, or disease after a remission.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Neoplasm, Residual: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)Cladribine: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Inhibitory Concentration 50: The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture.Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Thrombocytopenia: A subnormal level of BLOOD PLATELETS.Interferons: Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Injections, Subcutaneous: Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Treatment Failure: A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Drug Synergism: The action of a drug in promoting or enhancing the effectiveness of another drug.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.

*  Cladribine - Wikipedia
Cladribine is activated only by lymphocytes, and non-activated cladribine is removed quickly from all other cells. This means ... Cladribine is used for as a first and second-line treatment for symptomatic hairy cell leukemia and for B-cell chronic ... Cladribine, sold under the brand name Leustatin among others, is a medication used to treat hairy cell leukemia (HCL, leukemic ... Ivax to Develop Cladribine for Multiple Sclerosis Jennifer Bayot for the New York Times. July 26, 2005 Teva to Acquire Ivax, ...
*  Cladribine and clofarabine Drug Interactions - Drugs.com
A Moderate Drug Interaction exists between cladribine and clofarabine. View detailed information regarding this drug ... Using cladribine together with clofarabine may increase the risk of serious infections. Talk to your doctor if you have any ...
*  Mavenclad (cladribine) | MS Trust
... cladribine) is a disease modifying drug treatment for relapsing remitting multiple sclerosis. Read more about Mavenclad in this ... Other name: cladribine. Mavenclad is a disease modifying drug for very active relapsing remitting MS. You take Mavenclad as a ... Cladribine tablets for treating relapsing - remitting multiple sclerosis [TA493]. NICE Technology Appraisal Guidance 493 Full ... A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.. New England Journal of Medicine 2010;362(5): ...
*  Cladribine - Multiple Sclerosis - HealingWell.com Forum
Has anyone heard of this ms drug "Cladribine"? It is an oral therapy, particularly one that has no short term side effects. It ... HealingWell.com Forum , Diseases & Conditions , Multiple Sclerosis , Cladribine Select A Location. ****** Top of the Forum ... is suggested that it is easy to use and that oral Cladribine, will have a major impact on the treatment of MS. ...
*  Pharmacological basis for cladribine resistance
Cladribine, unlike many other drugs, is toxic to both dividing and indolent lymphoid malignancies. Cladribine is a prodrug and ... 5'-Nucleotidase (5'-NT) dephosphorylates cladribine-MP and the accumulation of cladribine-TP depends on the ratio of dCK and 5 ... The cytotoxicity mainly depends on the accumulation of cladribine-triphosphates (TP) after phosphorylation of cladribine-MP by ... Finally, cladribine resistance may be a consequence of a defective induction of apoptosis. In spite of the fact that more than ...
*  Chemical Summary for Cladribine
This database and website are updated and enhanced by Pesticide Action Network North America (PANNA). The project is made possible by our Sponsors and by PANNA general funds. We need your support to maintain and improve this system. Please support the database and website - donate to PANNA ...
*  Cladribine - UNM Comprehensive Cancer Center
How is cladribine typically given (administered)? Cladribine is given intravenously (into a vein) as a continous infusion over ... What is the mechanism of action? Cladribine belongs to a group of drugs called antimetabolites. Cladribine produces its anti- ... For which conditions is this drug approved? Cladribine is FDA approved for the treatment of hairy cell leukemia and chronic ... Generic Name: Cladribine (KLAD-rah-been), 2CdA, 2-Chlorodeoxyadenosine. Trade Name: Leustatin® ...
*  Cladribine for Injection - Pharmasave
Cladribine is used to treat a type of blood cancer known as hairy cell leukemia. Cladribine fights cancer by preventing the ... Do not use cladribine if you are allergic to cladribine or any ingredients of the medication. ... Nerve damage: High doses of cladribine, and cladribine used with other treatments for cancer have been associated with damage ... The recommended dose of cladribine varies according to body weight. The medication is usually given at a dose of 0.09 mg per kg ...
*  NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
... Thursday, November 9, 2017 General News ... The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo ... About MAVENCLAD In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD (Cladribine Tablets ... The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate ...
*  European Commission Grants Approval for Mavenclad (Cladribine Tablets) | Press release Merck KGaA
The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study: a two-year Phase III placebo-controlled study designed to evaluate ... Infections Cladribine can reduce the body's immune defence and may increase the likelihood of infections. HIV infection, active ... Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first ... MAVENCLAD® (cladribine tablets) is approved in the European Union for the treatment of highly active relapsing multiple ...
*  Expert Opinion: Recent Approval of Cladribine in EU
Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert Opinion: Recent Approval of Cladribine in EU. Be part of the knowledge.™. *Log In ... Professor Ralf Gold offers unique insight into the recent EU approval of Cladribine, a treatment for active relapsing multiple ... Expert insight into the recent approval of Cladribine for active relapsing multiple sclerosis. ...
*  cladribine : Information on Uses, Dosage & Side Effects
cladribine (generic name). Leustatin (brand name). This medicine reduces the growth of cancer cells and can suppress the immune ... CLADRIBINE (KLA dri been) is a chemotherapy drug. This medicine reduces the growth of cancer cells and can suppress the immune ... an unusual or allergic reaction to cladribine, benzyl alcohol, other medicines, foods, dyes, or preservatives ...
*  Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
No prior cladribine. Endocrine therapy:. - Not specified. Radiotherapy:. - Not specified. Surgery:. - Not specified. ... administration of cladribine in patients with hairy cell leukemia.. OUTLINE: This is a randomized, multicenter study. Patients ... Arm I: Patients receive daily subcutaneous bolus injections of cladribine (2-CDA) for 5. days (standard dose).. - Arm II: ...
*  Leustatin (Cladribine Injection For Intravenous Infusion Only) Patient Information: Side Effects and Drug Images at RxList
Cladribine Injection For Intravenous Infusion Only), drug imprint information, side effects for the patient. ... What is cladribine (Cladribine Novaplus, Leustatin)?. *What are the possible side effects of cladribine (Cladribine Novaplus, ... How is cladribine given (Cladribine Novaplus, Leustatin)?. Cladribine is injected into a vein through an IV. You will receive ... What is cladribine (Cladribine Novaplus, Leustatin)?. Cladribine is a cancer medication that interferes with the growth and ...
*  Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia - Full Text View - ClinicalTrials.gov
Cladribine with immediate Rituximab. Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion ... Non-randomized group receving Cladribine with immediate Rituximab. Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. ... Drug: Cladribine Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the ... To compare cladribine plus rituximab vs cladribine alone in terms of 1) initial MRD-free survival and disease-free survival, ...
*  Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
OUTLINE: This is a multicenter, dose-escalation study of cladribine.. Patients receive bryostatin 1 IV continuously on days 1-3 ... Cohorts of 3-6 patients receive escalating dose levels of cladribine until the maximum. tolerated dose (MTD) is determined. The ... Determine the maximum tolerated dose of cladribine when administered after bryostatin 1. in patients with relapsed chronic ... immediately followed by cladribine. IV continuously on days 4-8. Courses repeat every 4 weeks in the absence of disease. ...
*  Cladribine tablets
Ive searched the web and read articles around the trials with Cladribine and ... ... Hi Does anybody have any experience with Cladribine tablets? I saw a new Neuro yesterday and I think he will push for me to use ... Cladribine tablets. by Luvsadonut » Thu Jan 19, 2017 7:22 am Hi. Does anybody have any experience with Cladribine tablets? I ... There are 205 results for cladribine.. search.php?keywords=Cladribine&terms=all&author=&sc=1&sf=all&sk=t&sd=d&sr=posts&st=0&ch= ...
*  Mavenclad (cladribine) approved for use by the NHS in England and Wales | MS Trust
... cladribine) as a treatment for people with highly active relapsing MS on the NHS in England and Wales. ... About cladribine. Cladribine is a disease modifying drug for people with relapsing remitting MS. It works by reducing the ... Mavenclad (cladribine) has been approved as a treatment for people with highly active relapsing MS on the NHS in England and ... The NHS in England are expected to provide funding for cladribine within three months of its approval, and the NHS in Wales ...
*  Mavenclad (cladribine) available immediately in England for highly active relapsing multiple sclerosis | MS Trust
NICE has recommended that cladribine can be prescribed only if you have:. *rapidly evolving severe relapsing remitting MS (at ... Mavenclad (cladribine) available immediately in England for highly active relapsing multiple sclerosis. 09 November 2017 ... Mavenclad (cladribine) approved for use by the NHS in England and Wales ... NHS England and Merck have reached an agreement that people eligible for treatment can access Mavenclad (cladribine) ...
*  Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) - No Study Results Posted -...
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML). The recruitment status of this ...
*  Cladribine Phase-II results
Cladribine results by bromley » Fri Jan 23, 2009 4:46 am 11 Replies. 2833 Views. Last post by dignan Sat Jan 24, 2009 12:25 pm ... Oral cladribine Phase III by bromley » Tue Jan 16, 2007 2:21 am 2 Replies. 2126 Views. Last post by connieb Tue Jan 16, 2007 7: ... Cladribine - Phase III results by Frank » Thu Apr 30, 2009 3:42 am 3 Replies. 2389 Views. Last post by Needled Thu Apr 30, 2009 ... Phase III Trial of Oral Cladribine Starts by Dunmann » Thu May 04, 2006 7:03 am 6 Replies. 2646 Views. Last post by NHE Tue May ...
*  Cladribine - Phase III results
Cladribine, appears effective, but cancer cases raise concerns Merck KGaA reported late-stage data showing that its cladribine ... Cladribine results by bromley » Fri Jan 23, 2009 4:46 am 11 Replies. 2767 Views. Last post by dignan Sat Jan 24, 2009 12:25 pm ... Cladribine Phase-II results by Frank » Wed Apr 23, 2008 7:18 am 3 Replies. 2258 Views. Last post by gwa Wed Apr 23, 2008 2:23 ... Oral cladribine Phase III by bromley » Tue Jan 16, 2007 2:21 am 2 Replies. 2097 Views. Last post by connieb Tue Jan 16, 2007 7: ...
*  Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis
Once-daily cladribine consisted of administration of one or two 10 mg tablets. Subjects received two courses of cladribine ... CLARITY (CLAdRIbine Tablets Treating MS OrallY), a Phase III trial, has demonstrated that short-term oral cladribine decreases ... However, cladribine is resistant to the effects of adenosine deaminase. Following cladribine administration, lymphocytes will ... This resulted in patients taking cladribine tablets for 8-20 days during the first 48 weeks. Both cladribine groups received ...
*  A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active...
Experimental: Cladribine 3.5 mg/kg, IFN-beta Drug: Cladribine Subjects will receive cladribine tablets orally as cumulative ... Has an allergy or hypersensitivity to gadolinium, to cladribine or any of its excipients, or IFN-beta or any of its excipient(s ... Cladribine. Interferon beta-1a. Interferon beta-1b. Antineoplastic Agents. Antiviral Agents. Anti-Infective Agents. Immunologic ... Subjects will be randomized in a 2:1 fashion to receive up to 4 cycles of oral cladribine or matching placebo in combination ...
*  Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at...
About MAVENCLAD(TM) (Cladribine Tablets) Cladribine Tablets is a short-course oral therapy that is believed to selectively and ... The clinical development program for Cladribine Tablets includes: - The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study: ... extended administration of Cladribine Tablets for up to four years. - ORACLE MS (ORAl CLadribine in Early MS) study: a two-year ... 15 Cladribine Tablets Presentations Abstract/ Presentation Title Lead Author Poster # Date/Time/Session Efficacy of cladribine ...

Hairy cell leukemiaSapacitabineB-cell chronic lymphocytic leukemiaATC code J04: ==J04A Drugs for treatment of tuberculosis==VidarabineAntileukemic drug: Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include:Lymphoid leukemiaChlorambucilToralizumab: IDEC}}Katowice International Fair: Katowice International Fair () is an international trade fair in Katowice and one of the largest in Poland (the largest being the Poznań International Fair). Few dozen events are organized there each year, with the participation of some 4,500 companies.Overwhelming post-splenectomy infection: An overwhelming post-splenectomy infection (OPSI) is a rare but rapidly fatal infection occurring in individuals following removal of the spleen. The infections are typically characterized by either meningitis or sepsis, and are caused by encapsulated organisms including Streptococcus pneumoniae.Endodontic retreatment: Endodontic retreatment describes a dental root canal procedure that is carried out on a tooth that has previously had root canal treatment. For this reason it is also called "repeat root canal treatment".Low-dose chemotherapy: Low-dose chemotherapy is being studied/used in the treatment of cancer to avoid the side effects of conventional chemotherapy. Historically, oncologists have used the highest possible dose that the body can tolerate in order to kill as many cancer cells as possible.Energy charge: Energy charge is an index used to measure the energy status of biological cells. It is related to ATP, ADP and AMP concentrations.DaunorubicinWorking Formulation: The Working formulation is an obsolete classification of non-Hodgkin lymphomas, first proposed in 1982. It has since been replaced by other lymphoma classifications, the latest published by the WHO in 2008, but is still used by cancer agencies for compilation of lymphoma statistics.CytarabineCyclic neutropeniaLarge-cell lymphomaCancer survival rates: Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others.Immunosuppressive drug: Immunosuppressive drugs or immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system. They are used in immunosuppressive therapy to:Minimally differentiated acute myeloblastic leukemiaHeparin-induced thrombocytopeniaInterferon: :24-187 :24-185 :24-186Subcutaneous injectionOsmotic controlled-release oral delivery system: OROS (Osmotic [Controlled] Release Oral [Delivery] System) is a controlled release oral drug delivery system in the form of a tablet. The tablet has a rigid water-permeable jacket with one or more laser drilled small holes.Clinical endpoint: In a clinical research trial, a clinical endpoint generally refers to occurrence of a disease, symptom, sign or laboratory abnormality that constitutes one of the target outcomes of the trial, but may also refer to any such disease or sign that strongly motivates the withdrawal of that individual or entity from the trial, then often termed humane (clinical) endpoint.Tumor progression: Tumor progression is the third and last phase in tumor development. This phase is characterised by increased growth speed and invasiveness of the tumor cells.ABCD rating: ABCD rating, also called the Jewett staging system or the Whitmore-Jewett staging system, is a staging system for prostate cancer that uses the letters A, B, C, and D.Concentration effect: In the study of inhaled anesthetics, the concentration effect is the increase in the rate that the Fa(alveolar concentration)/Fi(inspired concentration) ratio rises as the alveolar concentration of that gas is increased. In simple terms, the higher the concentration of gas administered, the faster the alveolar concentration of that gas approaches the inspired concentration.

(1/220) Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.

PURPOSE: Cladribine (2-chlorodeoxyadenosine, 2-CdA) has been reported to be effective in the treatment of low-grade lymphomas. The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine. PATIENTS AND METHODS: A total of 47 courses, or an average of four courses per patient, were administered to 12 patients (seven untreated, five relapsed) with 5 mg/m2 cladribine given as an intermittent two-hour infusion over five consecutive days for a maximum of six cycles every four weeks. RESULTS: Cladribine showed activity in patients with mantle-cell lymphomas, achieving a response rate of 58% (95% confidence interval (95% CI): 28%-85%). Myelosuppression was the major toxicity with 17% of grade 3 and 4 neutropenia. Thrombocytopenia was rare with only 2% of grade 3 and 4. CONCLUSION: These results demonstrate single-agent activity of cladribine in mantle-cell lymphomas using the intermittent two-hour infusion dosage regimen. To further improve treatment results, cladribine should be combined with other agents active in mantle-cell lymphomas.  (+info)

(2/220) Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.

BACKGROUND AND OBJECTIVE: It has been widely demonstrated that one single 7-day course continuous infusion (c.i.) 2-chlorodeoxyadenosine (2-CdA) at a dose of 0.1 mg/kg daily is dramatically effective in inducing high and prolonged complete remission (CR) rates in patients with hairy-cell leukemia (HCL). However, 2-CdA administration often results in severe neutropenia and lymphocytopenia both responsible for the infectious complications observed in these patients. We previously reported preliminary data regarding the effectiveness and toxicity of a modified protocol of 2-CdA administration (0.15 mg/kg 2 hours infusion once a week for 6 courses) in 25 HCL patients. This treatment schedule produced a similar overall response rate compared to standard 2-CdA regimen and appeared to be followed by a lower incidence of infectious episodes. In the present study we report response rate and toxicity of weekly 2CdA administration in a larger cohort of patients and with a longer follow-up. DESIGN AND METHODS: In a group of HCL patients with a pronounced decrease in neutrophils count (< 1 x 10(9)/L), we modified the standard protocol (0.1 mg/kg daily x 7 days c.i.) by administering 2-CdA at a dose of 0.15 mg/kg 2 hours infusion once a week for 6 courses. Thirty HCL patients, 24 males and 6 females with a median age of 56 years (range 37-76), entered into this protocol. Seventeen out of 30 patients were at diagnosis while the remaining 13 had been previously treated with alpha-interferon (alpha-IFN) (7), or 2-CdA (4) or deoxycoformycin (DCF) (2). RESULTS: Overall, 22/30 (73%) patients achieved CR and 8 (27%) partial remission (PR) with a median duration of response at the time of writing of 35 months, ranging from 6 to 58 months. Five patients (1 CR and 4 PR) have so far progressed. The treatment was very well tolerated. Five out of 30 patients (16%) developed severe neutropenia (neutrophils < 0.5 x 10(9)/L) and only in two of them we did register an infectious complication which required treatment with systemic antibiotics and granulocyte colony-stimulating factor (G-CSF). INTERPRETATION AND CONCLUSIONS: In conclusion, we confirm that weekly administration of 2-CdA at a dose of 0.15 mg/kg for 6 courses appears to be very effective in HCL inducing a high CR rate, similar to that observed with daily c.i. administration. CR durability and relapse/progression rates are also comparable to standard 2-CdA schedule. Moreover this new regimen seems to be safer in pancytopenic patients, markedly reducing life-threatening infectious complications.  (+info)

(3/220) Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.

The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg(-1) per day as a subcutaneous bolus injection on days 1-3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m(-2) on day 1 and oral prednisone 40 mg (m-2) on days 1-5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade >3 haematological complications occurred in five patients and WHO grade >3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies.  (+info)

(4/220) Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.

Cladribine treatment of hairy cell leukemia (HCL) is complicated by neutropenic fever in 42% of patients despite documented infections being relatively uncommon. We performed a study of priming filgrastim followed by cladribine and then filgrastim again to determine if filgrastim would lead to a reduction of neutropenia and febrile episodes. Thirty-five patients received filgrastim and cladribine and were compared with 105 historic controls treated with cladribine alone. Cladribine was administered at 0.1 mg/kg/d by continuous infusion for 7 days. Filgrastim was administered at 5 micrograms/kg/d subcutaneously on days -3, -2, and -1 and then again after the completion of cladribine until the absolute neutrophil count (ANC) was >/=2 x 10(9)/L on 2 consecutive days (days +8, +9, etc). After filgrastim priming, the median ANC increased from 0.9 x 10(9)/L to 2.26 x 10(9)/L (2.5-fold increase), and after cladribine, the median nadir ANC in the filgrastim-treated group was 0.53 x 10(9)/L compared with 0.29 x 10(9)/L among historic controls (P =. 04). The median number of days to an ANC greater than 1.0 x 10(9)/L was 9 days in the filgrastim-treated group versus 22 days among historic controls (P < 10(-5)). The percentage of febrile patients, number of febrile days, and frequency of admissions for antibiotics were not statistically different in the two groups. Filgrastim regularly increases the ANC in patients with HCL and shortens the duration of severe neutropenia after cladribine. This phase II study, with comparison to historical controls, failed to detect any clinical advantage from the use of filgrastim and cladribine in the treatment of HCL. Accordingly, the routine adjunctive use of filgrastim with cladribine in the treatment of HCL cannot be recommended.  (+info)

(5/220) Cladribine activity in adult langerhans-cell histiocytosis.

Langerhans-cell histiocytosis (LCH) results from the accumulation of tissue histiocytes derived from the same progenitor cells as monocytes. Because cladribine is potently toxic to monocytes, we conducted a phase II trial of cladribine. Cladribine was administered to 13 LCH patients at 0.14 mg/kg per day by 2-hour intravenous infusion for 5 consecutive days, every 4 weeks for a maximum of six courses. Median age was 42 years (range, 19 to 72) and median pretreatment disease duration was 99 months (range, 6 to 252). One patient was untreated, one had received prior prednisone only, one prior radiation only, six prior radiation and chemotherapy, and four prior surgery, radiation, and chemotherapy. Seven patients had cutaneous involvement, six multifocal osseous, six pulmonary, two each with soft tissue and nodal involvement, and four had diabetes insipidus. Of 13 patients, 12 were evaluable for response and all for toxicity. After a median of three courses (range, 1 to 6), seven (58%) patients achieved complete responses (two pathologic and five clinical) and two (17%) patients achieved partial responses; overall response rate, 75%. Median response follow-up duration was 33 months (range, 1 to 65). Seven patients experienced grade 3 to 4 neutropenia. Only one patient had a documented infection, dermatomal herpes zoster. At a median follow-up of 42 months (range, 5 to 76), 12 patients remain alive and one patient has died. Thus, cladribine has major activity in adult LCH and warrants further investigation in both pediatric and adult LCH as a single agent and in combination with other drugs.  (+info)

(6/220) Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia.

Several features are characteristic for hairy cell leukemia (HCL). Among those are pancytopenia, bone marrow fibrosis, and the appearance of a defined tumor cell phenotype in peripheral blood (PB), bone marrow (BM), and spleen. Hairy cells (HC) coexpress antigens specific for B lymphocytes and monocytes/macrophages and thus the malignant cell does not seem to be restricted to a defined lineage. When serum or bone marrow aspirate was screened by enzyme-linked immunosorbent assay (ELISA) for basic fibroblast growth factor (bFGF), specimen derived from HCL (serum: mean value, 29 pg/mL; BM aspirate: mean value, 641 pg/mL) contained significantly higher levels than those from healthy subjects. To study whether peripheral blood mononuclear cells (PBMC) derived from patients suffering from HCL and healthy donors (HD) were capable of producing bFGF, culture supernatant (conditioned medium, [CM]) was tested for the presence of this cytokine. While bFGF was not detectable in cell cultures from HD, HCL-derived CM contained relatively high levels of bFGF. CM was successfully used for stimulation of mesenchymal cell proliferation, which could be inhibited by a neutralizing anti-bFGF antibody. Cellular activation by pokeweed mitogen (PWM) or the combination of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) plus calcium ionophore (Ca-Ip) led to an enhanced mRNA expression. Results of Western blot experiments showed that HC synthesize at least three isoforms (approximately 18, 23, and 25 kD), but only the 23-kD isoform is exported. To assess the nature of the producer cell, double immunofluorescence analysis using a bFGF-specific and an anti-CD11c monoclonal antibody (MoAb) was undertaken. The majority of cells scoring positive for CD11c were also reactive with the anti-bFGF MoAb. Furthermore, enrichment of CD19/CD11c-positive cells correlated with enhanced bFGF levels, thereby supporting the argument for HC being the producer cells of bFGF. A biological function of bFGF in HCL might be mediation of chemoresistance, as 2-chlorodeoxyadenosine (2-CdA)-induced inhibition of cell proliferation can be reversed by bFGF. Endogenous bFGF production by HC is not affected by this purine analogue and 2-CdA-induced apoptosis is diminished in bFGF-producing HC as compared with normal PBMC. Therefore, bFGF expression by HC might be important for resistance to chemotherapy and survival of the malignant cells.  (+info)

(7/220) Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.

The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'-deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (+/- 15%, SE), compared to 88% (+/- 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.  (+info)

(8/220) Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.

The objective of the present study was to investigate the biochemical pharmacology of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)--a fluorinated analogue of cladribine [2-chloro-2'-deoxyadenosine, Leustatin (CdA)] with improved acid and metabolic stability--in human leukemic cell lines and in mononuclear cells isolated from patients with chronic lymphocytic leukemia (CLL) and acute myelocytic leukemia (AML). We have also made and characterized two cell lines that are not sensitive to the growth inhibitory and cytotoxic effects of CAFdA. Incubation of cells isolated from the blood of CLL and AML patients with various concentrations of CdA or of CAFdA accumulated CdA and CAFdA nucleotides in a dose-dependent manner. A significantly higher rate of phosphorylation to monophosphates was observed for CAFdA than for CdA in cells from CLL patients (n = 14; P = 0.04). The differences in the phosphorylation were even more pronounced for the respective triphosphates in both CLL (n = 14; P = 0.001) and AML (n = 4; P = 0.04) cells. Retention of CAFdA 5'-triphosphate (CAFdATP) was also longer than that for CdA 5'-triphosphate (CdATP) in cells from leukemic patients. The relative efficacy of CAFdA as a substrate for purified recombinant deoxycytidine kinase (dCK), the key enzyme in the activation of nucleoside analogues, was very high and exceeded that of CdA as well as the natural substrate, deoxycytidine, by a factor of 2 and 8, respectively. The Km for CAFdA with dCK was also lower than that for CdA, as measured in crude extracts from the human acute lymphoblastic leukemia cell line CCRF-CEM and the promyelocytic leukemia cell line HL60. Acquired resistance to CAFdA in HL60 and in CCRF-CEM cell lines was directly correlated to the decreased activity of the nucleoside phosphorylating enzyme, dCK. Resistant cells also showed a considerable degree of cross-resistance to analogues that were activated by dCK. These observations demonstrated that dCK phosphorylates CAFdA more efficiently than CdA. Furthermore, CAFdATP is apparently more stable than CdATP and the mechanisms of resistance to CAFdA are similar to those leading to CdA resistance. These results encourage studies on the clinical effect of CAFdA in lymphoproliferative diseases.  (+info)

  • Drug
  • The mechanisms underlying cladribine resistance are multifactorial, e.g. decreased nucleoside transport, decreased activity or deficiency of dCK, altered intracellular pools of competing nucleotides, altered regulation of ribonucleotide reductase and increased drug inactivation by 5'-NT. (diva-portal.org)
  • Cladribine is a disease modifying drug for people with relapsing remitting MS . It works by reducing the number of white blood cells, known as lymphocytes, which cause the nerve damage associated with MS. The drug is therefore able to slow down or stop the immune attack and reduce the damage to the brain and spinal cord. (mstrust.org.uk)
  • Phase
  • Only 4 HCL-specific trials are listed on Cancer.gov: a phase II trial of cladribine followed 4 weeks later by 8 weekly doses of rituximab, and phase I-II trials of recombinant immunotoxins targeting CD22 (BL22, HA22) and CD25 (LMB-2). (clinicaltrials.gov)
  • In a phase III study, cladribine reduced relapses by 58% compared to placebo and also reduced the risk of disability progression. (mstrust.org.uk)
  • patients
  • Patients with the CD25-negative variant (HCLv) respond poorly to initial cladribine but do respond to rituximab in anecdotal reports. (clinicaltrials.gov)
  • Patients in complete remission (CR) to cladribine have minimal residual disease (MRD) by immunohistochemistry of the bone marrow biopsy (BMBx IHC), a risk for early relapse. (clinicaltrials.gov)
  • In studies with limited follow-up, MRD detected by tests other than RQ-PCR can be eliminated by rituximab after cladribine in greater than 90 percent of patients, but MRD rates after cladribine alone are unknown. (clinicaltrials.gov)
  • Rituximab 375 mg/m2/week times 8 weeks, randomized half to begin day 1, then repeat for all patients with blood-MRD relapse at least 6 months after cladribine. (clinicaltrials.gov)
  • Stratification: 68 patients with 0 and 62 with 1 prior course of cladribine. (clinicaltrials.gov)
  • available
  • The purpose of this review was to elucidate and analyse the available data concerning mechanisms of resistance of cladribine with emphasis on recent advances in the characterization of activating and inactivating enzymes in the induction of resistance to cladribine. (diva-portal.org)
  • receive
  • If you miss an appointment to receive cladribine, contact your doctor as soon as possible to reschedule your appointment. (pharmasave.com)
  • Do not receive a "live" vaccine while using cladribine, and avoid coming into contact with anyone who has recently received a live vaccine. (rxlist.com)
  • Cladribine must be given slowly through an IV infusion, and you will receive it around the clock for 7 days in a row. (rxlist.com)
  • disease
  • To compare cladribine plus rituximab vs cladribine alone in terms of 1) initial MRD-free survival and disease-free survival, and 2) response to delayed rituximab for relapse, to determine if early rituximab compromises later response. (clinicaltrials.gov)
  • known
  • Cp-Cz Cl-719 cladribine (INN) Claforan (Sanofi-Aventis), also known as cefotaxime clamidoxic acid (INN) Clamohexal (Hexal Australia) [Au]. (wikipedia.org)
  • days
  • Year one - In the first course, cladribine pills are taken for four or five days consecutively at the beginning of the first month and then four or five days consecutively at the beginning of the second month. (mstrust.org.uk)